The Medicines Co. price target raised to $37 from $34 at Leerink Leerink raised its price target for The Medicines Co. after the company announced positive Phase 3 results of the PHOENIX trial of Cangrelor. The firm estimates Cangrelor could address a $200M U.S. market opportunity and reiterates an Outperform rating on the stock.
News For MDCO From The Last 14 Days
Check below for free stories on MDCO the last two weeks.
The Medicines Co. acquires Rempex Pharmaceuticals The Medicines Company announced that it has acquired Rempex Pharmaceuticals. The Medicines Company paid Rempex equity holders $140M in an upfront payment at the closing of the deal. In addition, The Medicines Company has agreed to pay Rempex equity holders milestone payments subsequent to the closing, including certain development and regulatory approval milestones totaling $214M, and commercial milestones totaling $120M.